The yearly MetaSystems Distributor Meeting (DM), brought into life in 2002 as a platform to gather all international partners of MetaSystems and other members of the global MetaSystems family, just ended last week. The DM is being organized in turns by MetaSystems Headquarters, MetaSystems USA (MGI), and MetaSystems Asia. Since MGI is celebrating its 25th anniversary in 2018 they decided to choose a special location: Nassau, The Bahamas!
Break Apart Probe - Triple Color
- Order Number
- Package Size
- 100 µl
The myelodysplastic syndromes and myeloproliferative disorders are associated with deregulated production of myeloid cells. According to WHO classification (2008) cytogenetic aberrations are observed in about 50 % of MDS cases. The most common aberrations are 5q-, 7/7q-, trisomy 8, del(20q), and inv(3) or t(3;3).
Chromosomal translocations involving the MECOM locus are a recurrent finding in myeloid leukemia and are associated with poor prognosis. Two common recurrent rearrangements affect the 3q26 locus. One is the inv(3)(q21q26) and the translocation t(3;3)(q21;q26), in which EVI1 overexpression is caused by juxtaposition of the EVI1 gene to enhancer elements of the Ribophorin gene at 3q21. EVI1 activation is also observed in the translocations t(3;12)(q26;p13) and t(3;21)(q26;q22) and is due to generation of the fusion genes ETV6/EVI1 and RUNX1/EVI1, respectively.
- Myelodysplastic Syndrome (MDS)
- Acute Myelogenous Leukemia (AML)
Two blue-green-orange (2BGO) fusion signals representing the two normal EVI1 loci.
Aberrant Cell (typical results):
One green-blue (1GB) signal and one separate orange (1O) signal from the translocated chromosome and one blue-green-orange (1BGO) fusion signal from the normal chromosome.
Aberrant Cell (typical results): One green-orange (1GO) signal and one separate blue (1B) signal from the translocated chromosome and one blue-green-orange (1BGO) fusion signal from the normal chromosome.
- De Melo et al (2007) Leukemia 22:434-437
- De Wer et al (2008) Haematologica 93:1903-1907
- De Braekeleer et al (2015) Future Oncology 11:1675-1686